Longitudinal COVID-19 profiling associates IL-1Ra and IL-10 with disease severity and RANTES with mild disease

<p><strong>Background</strong> Identifying immune correlates of COVID-19 disease severity is an urgent need for clinical management, vaccine evaluation and drug development. Here we present a temporal analysis of key immune mediators, cytokine and chemokines in blood of hospitalise...

Full description

Bibliographic Details
Main Authors: Zhao, Y, Qin, L, Zhang, P, Peng, Y, Ogg, G, Ho, L-P, McMichael, A, Knight, JC, Dong, T
Format: Journal article
Language:English
Published: American Society for Clinical Investigation 2020
_version_ 1826302787548348416
author Zhao, Y
Qin, L
Zhang, P
Peng, Y
Ogg, G
Ho, L-P
McMichael, A
Knight, JC
Dong, T
author_facet Zhao, Y
Qin, L
Zhang, P
Peng, Y
Ogg, G
Ho, L-P
McMichael, A
Knight, JC
Dong, T
author_sort Zhao, Y
collection OXFORD
description <p><strong>Background</strong> Identifying immune correlates of COVID-19 disease severity is an urgent need for clinical management, vaccine evaluation and drug development. Here we present a temporal analysis of key immune mediators, cytokine and chemokines in blood of hospitalised COVID-19 patients from serial sampling and follow up over four weeks.</p> <p><strong>Methods</strong> A total of 71 patients with laboratory-confirmed COVID-19 admitted to Beijing You’an hospital in China with either mild (53 patients) or severe disease (18 patients) were enrolled with 18 healthy volunteers. We measured 34 immune mediators, cytokines and chemokines in peripheral blood every 4-7 days over one month per patient using a bio-plex multiplex immunoassay.</p> <p><strong>Results</strong> We found that the chemokine RANTES(CCL5) was significantly elevated, from an early stage of the infection, in patients with mild but not severe disease. We also found that early production of inhibitory mediators including IL-10 and IL-1RA were significantly associated with disease severity, and a combination of CCL5, IL-1Ra and IL-10 at week 1 may predict patient outcomes. The majority of cytokines that are known to be associated with the cytokine storm in virus infections such as IL-6 and IFN-gamma were only significantly elevated in the late stage of severe COVID-19 illness. TNF- alpha and GM-CSF showed no significant differences between severe and mild cases.</p> <p><strong>Conclusion</strong> Together our data suggest early intervention to increase expression of CCL5 may prevent patients from developing severe illness. Our data also suggest that measurement of levels of CCL5, as well as IL-1Ra, IL-10 in blood individually and in combination might be useful prognostic bio-markers to guide treatment strategies.</p>
first_indexed 2024-03-07T05:52:45Z
format Journal article
id oxford-uuid:e9757caf-2e9b-4e7b-9f19-08b077c31820
institution University of Oxford
language English
last_indexed 2024-03-07T05:52:45Z
publishDate 2020
publisher American Society for Clinical Investigation
record_format dspace
spelling oxford-uuid:e9757caf-2e9b-4e7b-9f19-08b077c318202022-03-27T10:54:46ZLongitudinal COVID-19 profiling associates IL-1Ra and IL-10 with disease severity and RANTES with mild diseaseJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:e9757caf-2e9b-4e7b-9f19-08b077c31820EnglishSymplectic ElementsAmerican Society for Clinical Investigation 2020Zhao, YQin, LZhang, PPeng, YOgg, GHo, L-PMcMichael, AKnight, JCDong, T<p><strong>Background</strong> Identifying immune correlates of COVID-19 disease severity is an urgent need for clinical management, vaccine evaluation and drug development. Here we present a temporal analysis of key immune mediators, cytokine and chemokines in blood of hospitalised COVID-19 patients from serial sampling and follow up over four weeks.</p> <p><strong>Methods</strong> A total of 71 patients with laboratory-confirmed COVID-19 admitted to Beijing You’an hospital in China with either mild (53 patients) or severe disease (18 patients) were enrolled with 18 healthy volunteers. We measured 34 immune mediators, cytokines and chemokines in peripheral blood every 4-7 days over one month per patient using a bio-plex multiplex immunoassay.</p> <p><strong>Results</strong> We found that the chemokine RANTES(CCL5) was significantly elevated, from an early stage of the infection, in patients with mild but not severe disease. We also found that early production of inhibitory mediators including IL-10 and IL-1RA were significantly associated with disease severity, and a combination of CCL5, IL-1Ra and IL-10 at week 1 may predict patient outcomes. The majority of cytokines that are known to be associated with the cytokine storm in virus infections such as IL-6 and IFN-gamma were only significantly elevated in the late stage of severe COVID-19 illness. TNF- alpha and GM-CSF showed no significant differences between severe and mild cases.</p> <p><strong>Conclusion</strong> Together our data suggest early intervention to increase expression of CCL5 may prevent patients from developing severe illness. Our data also suggest that measurement of levels of CCL5, as well as IL-1Ra, IL-10 in blood individually and in combination might be useful prognostic bio-markers to guide treatment strategies.</p>
spellingShingle Zhao, Y
Qin, L
Zhang, P
Peng, Y
Ogg, G
Ho, L-P
McMichael, A
Knight, JC
Dong, T
Longitudinal COVID-19 profiling associates IL-1Ra and IL-10 with disease severity and RANTES with mild disease
title Longitudinal COVID-19 profiling associates IL-1Ra and IL-10 with disease severity and RANTES with mild disease
title_full Longitudinal COVID-19 profiling associates IL-1Ra and IL-10 with disease severity and RANTES with mild disease
title_fullStr Longitudinal COVID-19 profiling associates IL-1Ra and IL-10 with disease severity and RANTES with mild disease
title_full_unstemmed Longitudinal COVID-19 profiling associates IL-1Ra and IL-10 with disease severity and RANTES with mild disease
title_short Longitudinal COVID-19 profiling associates IL-1Ra and IL-10 with disease severity and RANTES with mild disease
title_sort longitudinal covid 19 profiling associates il 1ra and il 10 with disease severity and rantes with mild disease
work_keys_str_mv AT zhaoy longitudinalcovid19profilingassociatesil1raandil10withdiseaseseverityandranteswithmilddisease
AT qinl longitudinalcovid19profilingassociatesil1raandil10withdiseaseseverityandranteswithmilddisease
AT zhangp longitudinalcovid19profilingassociatesil1raandil10withdiseaseseverityandranteswithmilddisease
AT pengy longitudinalcovid19profilingassociatesil1raandil10withdiseaseseverityandranteswithmilddisease
AT oggg longitudinalcovid19profilingassociatesil1raandil10withdiseaseseverityandranteswithmilddisease
AT holp longitudinalcovid19profilingassociatesil1raandil10withdiseaseseverityandranteswithmilddisease
AT mcmichaela longitudinalcovid19profilingassociatesil1raandil10withdiseaseseverityandranteswithmilddisease
AT knightjc longitudinalcovid19profilingassociatesil1raandil10withdiseaseseverityandranteswithmilddisease
AT dongt longitudinalcovid19profilingassociatesil1raandil10withdiseaseseverityandranteswithmilddisease